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Highlights 29 
 30 
x The venom proteome of the monocled cobra, Naja kaouthia, is presented 31 
x Most abundant venom components are three-finger toxins (neurotoxins and 32 
cytotoxins) and phospholipases A2 33 
x Toxicity (LD50) screening identified three-finger toxins as the most medically 34 
relevant of this venom 35 
x IgG response from a self-immunized human was significant against several toxins, 36 
although weak against those with higher toxicity  37 
38 
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Abstract 39 
 The venom proteome of the monocled cobra, Naja kaouthia, from Thailand, was 40 
characterized by RP-HPLC, SDS-PAGE, and MALDI-TOF-TOF analyses, yielding 38 41 
different proteins that were either identified or assigned to families. Estimation of relative 42 
protein abundances revealed that venom is dominated by three-finger toxins (77.5%; 43 
including 24.3% cytotoxins and 53.2% neurotoxins) and phospholipases A2 (13.5%). It also 44 
contains lower proportions of components belonging to nerve growth factor, 45 
ohanin/vespryn, cysteine-rich secretory protein, C-type lectin/lectin-like, nucleotidase, 46 
phosphodiesterase, metalloproteinase, L-amino acid oxidase, cobra venom factor, and 47 
cytidyltransferase protein families. Small amounts of three nucleosides were also 48 
evidenced: adenosine, guanosine, and inosine. The most relevant lethal components, 49 
categorized by means of a 'toxicity score', were   α-neurotoxins, followed by 50 
cytotoxins/cardiotoxins. IgGs isolated from a person who had repeatedly self-immunized 51 
with a variety of snake venoms were immunoprofiled by ELISA against all venom 52 
fractions. Stronger responses against larger toxins, but lower against   the  most   critical   α-53 
neurotoxins were obtained. As expected, no neutralization potential against N. kaouthia 54 
venom was therefore detected. Combined, our results display a high level of venom 55 
complexity, unveil the most relevant toxins to be neutralized, and provide prospects of 56 
discovering human IgGs with toxin neutralizing abilities through use of phage display 57 
screening. 58 
(199 words) 59 
60 
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1. Introduction 61 
 Snakebite is a serious medical condition affecting a large number of people 62 
worldwide; especially in impoverished rural areas of Asia, Africa and Latin America 63 
(Gutiérrez et al., 2006; Warrell, 2010a). Asia is the continent where the majority of these 64 
bites take place, and also where most deaths occur (Alirol et al., 2010; Chippaux, 1998; 65 
Kasturiratne et al., 2008). Currently there are 29 recognized extant species of terrestrial 66 
cobras assigned to the genus Naja (Utez and Hošek, 2015). Of these, 11 species are found 67 
in Asia, and 18 inhabit Africa (Utez and Hošek, 2015; Wallach et al., 2009). Among the 68 
cobras, Naja kaouthia (monocled cobra) is widespread in southern Asia and responsible for 69 
a significant part of the bites recorded (Viravan et al., 1986; Warrell, 1995; Kulkaew et al., 70 
2009). A study in Bangladesh discovered records of 764 snakebites during 1988-1989, of 71 
which 34% of the 168 deaths (22% case fatality) were attributed to the cobras Naja naja 72 
and N. kaouthia (Warrell, 2010b). N. kaouthia occurs from north-eastern India, Bangladesh 73 
and Bhutan, across southern China, southward to northern Peninsular Malaysia (Prakash et 74 
al., 2012; Wüster, 1996) and is common in most of its range (Stuart and Wogan, 2012). N. 75 
kaouthia is adapted to a broad range of habitats, including agricultural land, human 76 
settlements, and bigger cities. However, its natural habitat includes paddy fields, swamps, 77 
mangroves, grasslands, scrublands and forest (Stuart and Wogan, 2012). The diet of N. 78 
kaouthia covers a broad range of animals from frogs, snakes, small birds to mammals (Cox 79 
et al., 1998), and even fish (Kyi and Zug, 2003).  N. kaouthia is assessed as Least Concern 80 
at IUCN Red List of Threatened Species because of its large distribution, tolerance of a 81 
broad range of modified habitats, and is reported to be in abundance (Stuart and Wogan, 82 
2012). In Thailand it has been reported that many cases of hospitalization due to snakebite 83 
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were caused by N. kaouthia (Kulkeaw et al., 2009). Human envenomings by N. kaothia are 84 
predominantly characterized by neuromuscular paralysis which in severe cases ends up in 85 
respiratory paralysis, and by local tissue damage, i.e. swelling, necrosis and blistering 86 
(Warrell, 1995; Wongtongkam et al., 2005). 87 
 Enzymatic activities and toxicity of the venom of N. kaouthia have previously been 88 
studied (Pakmanee et al., 1998; Mukherjee and Maity, 2001; Das et al., 2013). Furthermore, 89 
a qualitative proteome of the venom has been reported showing the presence of 61 proteins 90 
belonging to 12 protein families (Kulkaew et al., 2007). The most prominent component is 91 
the long D-neurotoxin D-cobratoxin (Richard et al., 2013), constituting about 25% of the 92 
venom (Kulkaew et al., 2009) and belonging to the three-finger toxin family, of which N. 93 
kaouthia venom has several other members (Kulkaew et al., 2007). Other proteins that have 94 
been studied include phospholipases A2 (PLA2s) (Joubert and Taljaard, 1980a; Reali et al., 95 
2003; Doley and Mukherjee, 2003), L-amino acid oxidases (Tan and Swaminathan, 1992; 96 
Sakurai et al., 2001), cardiotoxins (Joubert and Taljaard, 1980b; Fletcher et al., 1991; 97 
Debnath et al., 2010; Jamunaa et al., 2012), and nerve growth factors (Kukhtina et al., 98 
2001). However, a proteomic analysis of this venom that integrates an estimation of relative 99 
protein abundances together with a detailed screening of the toxicity of its various 100 
components, is pending. An integrated functional and proteomic characterization of N. 101 
kaouthia venom is relevant not only for a deeper understanding of the composition of the 102 
venom and its relationships to toxicity, but also to establish a basic platform for 103 
antivenomic analyses. 104 
 Developing more potent antivenoms with better safety profiles is of medical 105 
relevance. Besides the traditional animal-derived antivenoms generated by immunization of 106 
horses with pools of snake venoms (Gutiérrez et al., 2011), various alternative approaches 107 
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have been pursued at the experimental level in order to generate more specific antibody-108 
based therapies aimed at neutralizing the most important toxins in the venom. One 109 
approach has been to raise murine antibodies specific towards relevant N. kaouthia toxins 110 
(Charpentier et al., 1990; Masathien et al., 1994). Another approach for identifying potent 111 
antitoxins is phage display screening (Roncolato et al., 2015). By using this methodology, 112 
inhibitors against N. kaouthia toxins have been identified for both PLA2s (Chavanayarn et 113 
al., 2012) and α-cobratoxin (Stewart et al., 2007; Kulkaew et al., 2009; Richard et al., 114 
2013). These studies discovered inhibitors through screening of phage display libraries 115 
based on heavy chain fragments obtained from llama. Although promising, it could, 116 
however, be argued that llama-derived inhibitors, despite being much smaller than whole 117 
IgG antibodies and therefore likely to be less immunogenic, are still non-human. An 118 
alternative to overcome this problem is based on modern antibody humanization procedures 119 
(Safdari et al., 2013). In another study, inhibitors based on human single chain Fv (scFv) 120 
fragments from non-immunized donors were developed (Kulkaew et al., 2009). These scFv 121 
fragments were not effective in rescuing mice injected with venom, which is likely to be 122 
due to naïve origin of the gene library for these fragments, since none of the human donors 123 
had been exposed to snake venom. Thus, the search for novel approaches to generate 124 
human antibodies against cobra venom toxins remains a challenge. 125 
 With this study, we report for the first time a venomics-based quantitative 126 
estimation of the proteome and a full protein lethality profile for N. kaouthia venom, in 127 
order to lay the foundation for developing a recombinant antivenom by identifying the most 128 
relevant toxins present in this venom. Furthermore, we uncover the presence of human IgG 129 
antibodies specific to N. kaouthia venom in the serum obtained from a unique individual 130 
exposed to low doses of a wide variety of snake venoms over a period of more than 25 131 
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years. The binding ability of his antibodies, as well as of those from a person bitten twice 132 
by the Southern Burrowing Asp, Atractaspis bibronii, was tested against the different 133 
venom fractions from N. kaouthia, in comparison to a healthy volunteer unexposed to snake 134 
venoms. Finally, the neutralizing ability against N. kaouthia venom of the purified human 135 
IgG antibodies was evaluated in a mouse model. 136 
 137 
2. Materials and Methods 138 
2.1 Snake venom 139 
 Naja kaouthia venom was obtained from Latoxan SAS, Valence, France. The 140 
venom is a pool collected from several specimens, originally from Thailand. 141 
 142 
2.2 Venom separation by reverse-phase HPLC and SDS-PAGE  143 
 Following   the   ‘snake   venomics’   analytical   strategy   (Calvete, 2011), crude venom 144 
was fractionated by a combination of RP-HPLC and SDS-PAGE separation steps. Venom 145 
(2 mg) was dissolved in 200 μL of water containing 0.1% trifluoroacetic acid (TFA; 146 
solution A) and separated by RP-HPLC (Agilent 1200) on a C18 column (250 x 4.6 mm, 5 147 
μm particle; Teknokroma). Elution was carried out at 1 mL/min by applying a gradient 148 
towards solution B (acetonitrile, containing 0.1% TFA): 0% B for 5 min, 0–15% B over 10 149 
min, 15–45% B over 60 min, 45–70% B over 10 min, and 70% B over 9 min, as previously 150 
described (Lomonte et al., 2014a). Manually collected fractions were dried in a vacuum 151 
centrifuge, redissolved in water, reduced with 5% E-mercaptoethanol at 100 °C for 5 min, 152 
and further separated by SDS-PAGE in 12% gels (Bio-Rad). Proteins were stained with 153 
colloidal Coomassie blue G-250, and gel images were acquired on a ChemiDoc® recorder 154 
using ImageLab® software (Bio-Rad). 155 
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 156 
2.3 Protein identification by tandem mass spectrometry of tryptic peptides 157 
 Protein bands were excised from the polyacrylamide gels and subjected to reduction 158 
(10 mM dithiothreitol), alkylation (50 mM iodoacetamide), and overnight in-gel digestion 159 
with sequencing grade trypsin (Sigma), in 50 mM ammonium bicarbonate at 37°C. The 160 
resulting tryptic peptides were extracted with 50% acetonitrile containing 1% TFA, and 161 
analyzed by MALDI-TOF-TOF on an AB4800-Plus Proteomics Analyzer (Applied 162 
Biosystems). Peptides   were   mixed   with   an   equal   volume   of   saturated   α-cyano-163 
hydroxycinnamic acid (in 50% acetonitrile, 0.1% TFA), and spotted (1 μL)  onto an Opti-164 
TOF 384-well plate, dried, and analyzed in positive reflector mode. TOF spectra were 165 
acquired using 1500 shots and a laser intensity of 3000. The ten most intense precursor ions 166 
were automatically selected and their TOF/TOF fragmentation spectra were acquired using 167 
500 shots at a laser intensity of 3900. External calibration in each run was performed with 168 
CalMix® standards (ABSciex) spotted onto the same plate. For protein identification, 169 
resulting spectra were searched against the UniProt/SwissProt database using ProteinPilot® 170 
v.4 and the Paragon® algorithm  (ABSciex)  at  ≥  95%  confidence,  or  manually  interpreted.  171 
Few peptide sequences with lower confidence scores were manually searched using 172 
BLAST (http://blast.ncbi.nlm.nih.gov) for protein similarity and protein family assignment. 173 
 RP-HPLC fractions corresponding to small molecules, eluting in the initial peaks of 174 
the chromatogram, were analyzed by ESI-MS/MS on a Q-Trap® 3200 instrument (Applied 175 
Biosystems).  Samples  (10  μL)  were  loaded  into  metal-coated capillary tips (Proxeon) and 176 
directly infused into a nano-ESI source (Protana) operated at 1300 V. Spectra were 177 
acquired in positive Enhanced Resolution mode. nESI-MS performed in this instrument 178 
was also used to determine the isotope-averaged mass of intact proteins in selected peaks 179 
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from the RP-HPLC separation. For this purpose, mass spectra were acquired in Enhanced 180 
Multicharge mode in the m/z range 700-1700, and deconvoluted with the aid of the 181 
Analyst® v.1.5 software (ABSciex). 182 
 183 
2.4 Relative protein abundance estimations 184 
 The relative abundances of the venom proteins identified were estimated by 185 
integrating the areas of their chromatographic peaks at 215 nm, using the ChemStation® 186 
software (Agilent), which correlates with peptide bond abundance (Calvete, 2011). For 187 
HPLC peaks containing several electrophoretic bands, their percentage distributions were 188 
assigned by densitometry, using ImageLab® (Bio-Rad). 189 
 190 
2.5 Nucleoside and FAD analysis 191 
 The presence of selected nucleosides (adenosine, inosine, guanosine), and flavine 192 
adenine dinucleotide (FAD) was determined by spiking a sample of 1 mg of venom with 10 193 
μg  of  each nucleoside or FAD, respectively, and separating it by reverse-phase HPLC as 194 
described in section 2.2. If the nucleoside or FAD peak coincided with a peak already 195 
present in a crude venom sample (as judged by the increment in the height of the peak), and 196 
if this venom peak showed an ESI-MS spectrum similar to that of the nucleoside or FAD, 197 
the identity of venom component was judged to be the same as the nucleoside or FAD. 198 
Further confirmation of the molecular identities of the nucleosides was obtained by 199 
acquiring their collision-induced dissociation MS/MS spectra in positive mode, using the 200 
Enhanced Product Ion tool of the Analyst v1.5 in the QTrap 3200 mass spectrometer as 201 
described (Laustsen et al., 2015). The abundance for nucleosides given in Table 1 is only 202 
indicative of an approximate value, due to differences in absorbance at 215 nm between 203 
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nucleosides and proteins. 204 
 205 
2.6 In vitro enzymatic activities 206 
2.6.1. Phospholipase A2 activity 207 
PLA2 activity was assayed on the monodisperse synthetic chromogenic substrate 4-208 
nitro-3-octanoyloxybenzoic acid (NOBA) (Holzer and Mackessy, 1996). Twenty-five μL 209 
containing   various   amounts   of   venom  were  mixed  with   200   μL   of   10  mM  Tris,   10  mM  210 
CaCl2,  0.1  M  NaCl,  pH  8.0,  and  25  μL  of  NOBA  to  achieve  a  final  substrate  concentration  211 
of 0.32 mM. Plates were incubated at 37 °C for 60 min, and absorbances were recorded at 212 
405 nm in a microplate reader. Samples were assayed in triplicates. 213 
 214 
2.6.3 Proteinase activity 215 
 Variable amounts of venom (10 to  40  μg)  were  added   to  100  μL  of  azocasein   (10  216 
mg/mL in 50 mM Tris–HCl, 0.15 M NaCl, 5 mM CaCl2 buffer, pH 8.0), and incubated for 217 
90  min   at   37   °C.  The   reaction  was   stopped  by   addition   of   200  μL  of   5%   trichloroacetic  218 
acid, and after centrifugation (5 min, 13,000 rpm),  150  μL  of supernatants were mixed with 219 
100   μL   of   0.5  M  NaOH,   and   absorbances  were   recorded   at   450   nm.   The   absorbance of 220 
azocasein incubated with distilled water alone was used as a blank, being subtracted from 221 
all readings (Wang et al. 2004). Samples were assayed in triplicates. 222 
 223 
2.7 Toxicological profiling 224 
2.7.1 Animals  225 
 In vivo assays were conducted in CD-1 mice, supplied by Instituto Clodomiro 226 
Picado, following protocols approved by the Institutional Committee for the Use and Care 227 
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of Animals (CICUA), University of Costa Rica. Mice were housed in cages for groups of 228 
4–8, and were provided food and water ad libitum. 229 
 230 
2.7.2 Toxicity of crude venom and isolated toxins 231 
 The lethality of the whole venom and fractions or isolated toxins was tested by 232 
intravenous (i.v.) injection in groups of four mice (18–20 g body weight). Various amounts 233 
of venom or fractions/toxins were dissolved in phosphate-buffered saline (PBS; 0.12 M 234 
NaCl, 0.04 M sodium phosphate buffer, pH 7.2), and injected in the caudal vein, using an 235 
injection volume of 100 µL. Then, deaths occurring within 24 hr were recorded. Median 236 
lethal dose (LD50) was calculated by probits (Finney, 1971), using the BioStat® software 237 
(AnalySoft). 238 
 The toxicity of venom fractions was initially screened by selecting a dose based on 239 
fraction abundance. The dose was selected to assess whether the fraction would score above 240 
or below 5 according to the Toxicity Score defined by Laustsen et al. (2015), which 241 
represents the ratio of protein fraction abundance (%) in the venom divided by its estimated 242 
LD50 in CD-1 mice by i.v. injection. Fractions that were not lethal at this dose (yielding a 243 
Toxicity Score < 5) were considered as having insignificant toxicity. All fractions that were 244 
lethal at this level, and some fractions killing mice at a Toxicity Score level between 1-5 245 
were further evaluated, and precise LD50 values were further determined for them. Groups 246 
of 3-5 mice per dose were used in order to minimize the use of experimental animals. 247 
 248 
2.8 Preparation of human IgGs and human serum 249 
2.8.1 Donor 1  250 
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 This donor has over a period of 25 year injected himself with sub-lethal amounts of 251 
venom from the following snakes: Viridovipera (formerly Trimeresurus) stejnegeri, 252 
Trimeresurus nebularis, T. macrops, T. popeorum, T. trigonocephalus, T. albolabris, T. 253 
venustus, Bothriechis schlegelii, Crotalus enyo enyo, Naja kaouthia, N. naja, N. siamensis, 254 
Agkistrodon contortrix, A. bilineatus, Bothrops asper, Crotalus oreganus, Crotalus 255 
oreganus helleri, Cerastes cerastes, and Micrurus fulvius. In the last 5 years, this individual 256 
has been injecting himself with venom from Naja kaouthia on an average of every 2 weeks. 257 
Brian Lohse has a written consent from the Danish scientific ethical council (H-3-2013-258 
FSP60) to use the blood sample from this donor according to the law of the ethical 259 
committee § 2.1. After having provided written and oral information about the project to 260 
this donor, written consent was given for obtaining blood samples and for performing the 261 
experiments included in the present work. The donor requested the inclusion of his name to 262 
be acknowledged in publications. 263 
 264 
2.8.2 Donor 2  265 
 Donor 2 is an entomologist, who was unfortunate to be bitten twice by the snake 266 
Atractaspis bibronii (Southern Burrowing Asp) during fieldwork in August 2013. After 267 
having provided written and oral information about the project to this donor, written 268 
consent was given for obtaining blood samples and for performing the experiments here 269 
included. The donor requested the inclusion of his name to be acknowledged in 270 
publications. 271 
 272 
2.8.3 Blood sampling for obtaining IgGs 273 
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 200 ml of blood was sampled from each donor in Vacuette® tubes of 4 mL, 274 
containing Z Serum Clot Activator (Greiner bio-one). Every tube was gently tilted up and 275 
down ten times as soon as it was filled with blood to ensure thorough mixing with the 276 
coagulation factor. The tubes were kept at room temperature until full coagulation (30 min). 277 
Then, tubes were centrifuged at 3000 g for 10 min, and the serum was transferred to 278 
cryotubes and stored at -20 °C. 279 
 280 
2.8.4 Protein A purification of IgG antibodies 281 
After filtration of serum through a 0.45 μm  membrane, the procedure accompanying 282 
the Protein A Antibody Purification Kit (PURE1A, Sigma-Aldrich) was followed in order 283 
to obtain human IgG antibodies in solution at physiological pH. IgG antibodies were stored 284 
at 4 °C. 285 
 286 
2.8.5 Preparation of human serum from healthy volunteer 287 
Blood was obtained from a healthy donor to serve as a negative control. After 288 
clotting, serum was separated by centrifugation, and stored at – 20 °C. 289 
 290 
2.9 Immunoreactivity of human IgGs against venom fractions by ELISA 291 
 Wells in MaxiSorp plates (NUNC, Roskilde, Denmark) were coated overnight with 292 
0.6 μg of each HPLC venom fraction dissolved in 100 μL PBS. Then, wells were blocked 293 
by adding 100 μL PBS containing 2% (w:v) bovine serum albumin (BSA, Sigma) and 294 
leaving the plates on a mixer at room temperature for 1 h. Plates were then washed five 295 
times with PBS. A dilution of each human IgG pool in PBS + 2% BSA was prepared such 296 
that the concentration of IgG proteins was 86  μg/mL (as measured by their absorbance at 297 
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280 nm on a NanoDrop® 2000c instrument, Thermo Scientific). Then, 100  μL of these IgG 298 
solutions were added to the wells, after which the plates were incubated for 2 h, followed 299 
by five additional washings with PBS. Then, 100 µL of a 1:2000 dilution of affinity-300 
purified goat anti-human IgG (gamma-chain specific) antibodies conjugated to alkaline 301 
phosphatase (Cappel, Organon Teknika) in PBS + 2% BSA was added to each well. The 302 
plates were incubated for 2 h, and then washed five times with FALC buffer (0.05 M Tris, 303 
0.15 M NaCl, 20 PM ZnCl2, 1 mM MgCl2, pH 7.4). Color development was achieved by 304 
the addition of 100 µL p-nitrophenyl phosphate (1 mg/mL in 9.7% v/v diethanolamine 305 
buffer, pH 9.8).  The absorbances at 405 nm were recorded (Multiskan FC, Thermo 306 
Scientific) at several time intervals. 307 
 308 
2.10 Neutralization studies with human IgGs 309 
 After purification according to section 2.8.4, the human IgGs were kept refrigerated. 310 
Six months later, 3 mL of IgGs were dialyzed against 2 L of PBS overnight and 311 
lyophilized. The IgGs were reconstituted in 500 µL PBS and the protein concentration was 312 
measured on NanoDrop to be 14 mg/ml. IgG was mixed with venom at a ratio of 78 mg 313 
IgG/mg venom and incubated at 37 ºC for 30 min. Aliquots of 120 µL of this mixture, 314 
containing 4 LD50s of venom, were then injected i.v. into a group of four mice (18-20 g) 315 
and deaths occurring within 24 hr were recorded. 316 
 317 
3.0 Results and Discussion 318 
3.1 Venomics 319 
A proteomic characterization of N. kaouthia venom coupled with an estimation of 320 
its protein relative abundances was, with this study, carried out for the first time. Twenty-321 
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eight peaks from the venom were resolved by RP-HPLC. The first three fractions eluting 322 
from the column were non-peptidic, while the remaining 25 peaks were further resolved 323 
into 50 protein bands by SDS-PAGE separation (Fig.1). In-gel digestion and MALDI-TOF-324 
TOF analysis of these yielded a total of 38 identified proteins, while only 4 remained 325 
unknown. Altogether, the unidentified venom components represent less than 1% of the 326 
total venom protein content, while the rest were either identified or assigned to protein 327 
families (Table 1). A previous qualitative proteomic profile was reported for this venom, 328 
describing matches to 61 orthologous proteins classified into 12 groups (Kulkaew et al., 329 
2007). Of these, oxoglutarate dehydrogenase complex was identified on the basis of a 330 
single peptide that matched such enzyme from a prokaryote (Burkholderia cenocepacia), 331 
while serum albumin likely corresponds to contaminating traces derived from slight trauma 332 
that may occur during venom collection (see for example Lomonte et al., 2014b). In 333 
addition, the previous study considered cardiotoxins and cytotoxins as two different protein 334 
groups, in spite of these two names being used to refer to the same type of toxins, 335 
structurally classified within the three-finger toxin family (Kini and Doley, 2010). Our 336 
results are concordant with the remaining eight protein families detected by Kulkaew et al. 337 
(2007), but further expand the proteomic profile of N. kaouthia venom with the addition of 338 
members belonging to the nerve growth factor, ohanin-like/vespryn, C-type lectin/lectin-339 
like, nucleotidase, phosphodiesterase, L-amino acid oxidase, and cytidyltransferase protein 340 
families (Table 1 and Fig.2), and moreover, providing a quantitative estimation of their 341 
relative abundances in the venom. 342 
Peaks 1 to 3 were analyzed by direct infusion using nESI-MS/MS, since they did 343 
not show proteins by gel electrophoresis. Peaks 2 and 3 had molecular masses of 268 Da 344 
and 283 Da, respectively, and the nucleoside analysis by HPLC (Fig.3) revealed their 345 
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identities as adenosine and guanosine, respectively. Also, a trace of inosine between peaks 346 
2 and 3 was detected by the nucleoside analysis by HPLC (Fig.3). 347 
All peptidic peaks were tested in vivo for acute toxicity, except for peaks 23 and 26, 348 
which yielded very low amounts of proteins (Table 2), and peaks 24, 27, and 28, which 349 
correspond to metalloproteinases, enzymes known to be inactivated by the RP-HPLC 350 
separation procedure. In Fig.2, the overall protein composition of the venom of N. kaouthia, 351 
expressed as percentage of total protein and nucleoside content, is represented. Two main 352 
families predominate in the venom: Three-finger toxins (3FTx; 77.5%, of which 24.3% are 353 
cytotoxins, the rest being neurotoxins) and PLA2s (PLA2; 13.5%). In partial agreement with 354 
previous findings, the major single component of the three-finger toxins was determined to 355 
be alpha-elapitoxin-Nk2a (D-cobratoxin), a long-chain neurotoxin. However, in our results, 356 
this toxin represented 32.3% of the whole venom, which is significantly higher than the 357 
reported values of 23-25% (Kulkaew et al., 2009). This increase might reflect either 358 
geographical variations in venom composition or differences in methodology. As other D-359 
neurotoxins, alpha-elapitoxin-Nk2a is able to bind to nicotinic receptors at the motor end-360 
plate of muscle fibers, thus generating a flaccid paralysis leading to respiratory failure and 361 
death (Ultsintong et al., 2009; Alkondon et al., 1990). This type of neurotoxin is 362 
responsible for the life-threatening neuromuscular paralysis in human victims of neurotoxic 363 
cobra bites (Warrell, 1995). 364 
An interesting finding, discovered by the lack of high acute toxicity in the rodent 365 
model (Table 2), and reinforced by the difference in human IgG binding in the ELISA 366 
assays (Fig.6) was that the protein identified in peak 10 as alpha-elapitoxin-Nk2a appears to 367 
correspond to a closely related homolog. In order to validate this, both peak 10 and peak 6 368 
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(known to contain alpha-elapitoxin-Nk2a) were analyzed by nESI-MS/MS (Fig.5), 369 
according to which their masses were 7619 and 7826 Da, respectively (alpha-elapitoxin-370 
Nk2a has a reported mass of 7831 Da according to: 371 
http://www.uniprot.org/uniprot/P01391). Thus, peak 10 should be a homolog of alpha-372 
elapitoxin-Nk2a sharing peptide sequences (Table 1), but different by 207 Da in total mass. 373 
Since the toxicity of this protein is markedly lower in comparison to alpha-elapitoxin-Nk2a, 374 
further studies to determine its complete amino acid sequence and bioactivities could be of 375 
interest, as it represents nearly 10% of the venom proteome. 376 
In addition to D-neurotoxins, other representatives of the three-finger toxin family 377 
detected in N. kaouthia venom proteome are the so-called   ‘cytotoxins’ (Table 1). These 378 
toxins are known to interact with and disrupt the integrity of plasma membrane of various 379 
cell types, thus inducing irreversible cell damage (Konshina et al., 2012). These cytotoxins 380 
are responsible for the local necrotic effect characteristic of envenomings by N. kaouthia 381 
(Warrell, 1995). Also, PLA2 is commonly an abundant component in the majority of elapid 382 
venom proteomes characterized so far, and it was detected in our proteomic analysis in N. 383 
kaouthia venom. PLA2 activity was confirmed for N. kaouthia venom in vitro, although it 384 
was significantly lower than for M. nigrocinctus, a Central American elapid species 385 
(Fig.4A). Elapid PLA2s have been shown to exert a number of toxicological effects, such as 386 
myonecrosis (Bhat and Gowda, 1989; Harris, 1991), anticoagulation (Kini, 2005; Doley 387 
and Mukherjee, 2003), inhibition of platelet aggregation (Clemetson et al., 2007), and 388 
edema (Wang and Teng, 1990). In the case of N. kaouthia venom, PLA2s might contribute 389 
to the local inflammatory and necrotizing effects observed in human patients. Furthermore, 390 
cardiotoxins and PLA2s act synergistically to induce cell membrane damage (Harvey et al., 391 
1983), thus potentiating the tissue damaging effect of the venom. Altogether, a high 392 
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proportion of the components of N. kaouthia venom belong to these two toxin families, i.e. 393 
three-finger toxins and PLA2s. This further supports the concept that high diversity within 394 
just a few toxin families may be a general theme within elapid venoms (Calvete, 2013; 395 
Laustsen et al., 2015). Such idea is supported also by findings of Vonk et al. (2013) on the 396 
genome of the elapid Ophiophagus hannah (king cobra), in which the three-finger toxins 397 
family was found to be highly diversified. 398 
In amounts each representing <2% of the total venom content, the venom also 399 
contains members of the nerve growth factor (NGF), Ohanin/vespryn (OHA), Cysteine-rich 400 
secretory protein (CRISP), C-type lectin/lectin-like (CTL), nucleotidase (NUCL), 401 
phosphodiesterase (PDE), metalloproteinase (MP), L-amino oxidase (LAO), Cobra venom 402 
factor (CVF), and Cytidyltransferase (CTT) families. The low content of proteinases is 403 
further supported by the negligible proteinase activity of the venom upon a general 404 
substrate such as azocasein (Fig.4B). Also, regarding non-peptidic material, small amounts 405 
were identified to be adenosine, inosine, and guanosine, which have also been detected in 406 
other snake venoms (Aird, 2002; Laustsen et al., 2015).  407 
The results of toxicity testing of the fractions are summarized in Table 2. 408 
Unsurprisingly, the lethality of the venom stems from the presence of potent α-neurotoxins 409 
and cytotoxins, with PLA2s playing a secondary role leading to local tissue damage at the 410 
bite wound. A Toxicity Score is shown in Table 2, which takes into account both potency 411 
and abundance. Toxins with a higher score, as estimated in mice, are expected to be of 412 
higher medical relevance. These are abundant and/or very potent, while toxins with a low 413 
score are less medically relevant. Based on this score, it is clear that alpha-elapitoxin-Nk2a 414 
is by far the toxin that is most clinically relevant to neutralize, with a value of 326. Some 415 
toxins have very low LD50s (particularly fractions 4 and 5), but due to their lower 416 
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abundance their Toxicity Scores are much lower. Others have intermediate LD50 potencies, 417 
but become relevant due to their high abundance (e.g. fraction 16). The cytotoxins present 418 
in the venom act by a different mechanism than the α-neurotoxins, providing N. kaouthia 419 
venom with a dual strategy for prey subduction. It is interesting to note that the 420 
accumulated Toxicity Scores for all toxins amount to the same value as the Toxicity Score 421 
for the whole venom. This is not the case for the venom from the related elapid, 422 
Dendroaspis polylepis, which shows evidence of synergism, and where the accumulated 423 
Toxicity Scores is considerably lower than the Toxicity Score of whole venom (indicating 424 
synergism between the toxins and not simply additive effect) (Laustsen et al., 2015). One 425 
interpretation of this finding could be that N. kaouthia venom does not exert significant 426 
synergism, but instead relies on two complementary strategies for acute toxicity. 427 
 In terms of therapeutic targets, based on their Toxicity Score, the most relevant 428 
toxins in N. kaouthia venom that should be neutralized by an effective antivenom are (in 429 
order of importance): alpha-elapitoxin-Nk2a (P01391), cobrotoxin-c (P59276) and 430 
cobrotoxin-b (P59275), and the homolog of three-finger toxin from Naja atra (E2IU03), 431 
while the cytotoxins are of less importance in terms of overall lethality, although they are 432 
likely to play a relevant role in local necrosis, and hence should be neutralized by 433 
antivenoms. In addition, neutralization of PLA2s should also be considered a priority in 434 
order to limit local tissue damage from envenomings. Thus, antivenomic studies with N. 435 
kaouthia venom should establish whether antivenoms are able to bind these toxins. 436 
 437 
3.2 Immunoreactivity of human IgGs against venom fractions 438 
 The isolated human IgGs from the unique individual who had self-injected small 439 
amounts of venom from various different snakes, including N. kaouthia, showed significant 440 
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binding ability to isolated venom fractions, clearly above the background established by 441 
serum of a healthy donor, or by IgGs from the donor bitten twice by a different snake 442 
species (Fig.6). It is evident that the antibody response of the individual exposed to N. 443 
kaouthia venom was higher against larger toxins present in later eluting peaks, while the 444 
response was limited against the most important α-neurotoxins (peaks 4, 5, and 6), which 445 
could be due to the low immunogenicity of small toxins (Fernández et al., 2011). Therefore, 446 
it was not surprising that IgGs were unable to neutralize the lethality of whole venom when 447 
mice were challenged with 4 LD50s mixed with IgGs at a level of 0.013 mg toxin per mg of 448 
IgGs. Nevertheless, it could be particularly interesting to further investigate these 449 
antibodies via phage display screening. In llamas, it has been shown that using naïve 450 
libraries for phage display screening did not yield high affinity inhibitors to snake toxins, 451 
while excellent inhibitors of alpha-elapitoxin-Nk2a were discovered this way, when a 452 
library from an immunized llama was used (Richard et al., 2013). Kulkeaw et al. (2009) 453 
were the first to report drug discovery effort using a human phage display library. However, 454 
they similarly did not find strong inhibitors of snake toxins, most likely given the fact that 455 
their library was naïve. Therefore, using the antibody genes from the unique donor to 456 
construct a phage display library, and subsequently screening this library, has the potential 457 
to yield toxin inhibitors of therapeutic value. Further studies of the donor's immune 458 
response against toxins from other snake species are warranted and may help direct phage 459 
display screening efforts towards the generation of new antibodies of human origin. 460 
 461 
4.0 Concluding remarks and outlook 462 
 Differing from previous proteomic studies on N. kaouthia venom, the present work 463 
combined the cataloguing of venom proteins with an estimation of their relative 464 
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abundances, together with an assessment of their lethal toxicity for mice. This approach 465 
uncovered that the most abundant group of proteins was three-finger toxins, followed by 466 
PLA2s. Based on an evaluation of the accumulation of Toxicity Scores and knowledge 467 
about toxin functions, the venom seems to have a dual strategy for prey subduction elicited 468 
by  α-neurotoxins and cytotoxins, between which pharmacological interaction is speculated 469 
only to be of additive value rather than synergism.  470 
ELISA immunoprofiling of human IgGs isolated from a human donor, who had 471 
repeatedly injected himself with snake venom from various different species, revealed 472 
presence of antibodies with high binding ability to several of the isolated venom fractions, 473 
although not against the medically most relevant toxins of N. kaouthia. Still, the presence 474 
of these antibodies opens the prospect of discovering inhibitors of therapeutic value. 475 
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Figure legends 678 
 679 
Figure 1: Separation of N. kaouthia (A) venom proteins by RP-HPLC (C), followed by 680 
SDS-PAGE (B). Two mg of venom were fractionated on a C18 column and eluted with an 681 
acetonitrile gradient (dashed line), as described in Methods. Fractions were further 682 
separated by SDS-PAGE under reducing conditions. Molecular weight markers (Mw) are 683 
indicated in kDa. Coomassie-stained bands were excised, in-gel digested with trypsin, and 684 
subjected to MALDI-TOF/TOF analysis for assignment to protein families, as shown in 685 
Table 1. 686 
 687 
Figure 2: Composition of N. kaouthia venom according to protein families, expressed as 688 
percentages of the total protein content. 3FTx: three-finger toxin; PLA2: phospholipase A2; 689 
NGF: nerve growth factor; OHA: Ohanin/vespryn; CRISP: Cysteine-rich secretory protein; 690 
CTL: C-type lectin/lectin-like; NUCL: nucleotidase; PDE: phosphodiesterase; MP: 691 
metalloproteinase; LAO: L-amino oxidase; CVF: Cobra venom factor; CTT: 692 
Cytidyltransferase; UNK: Unidentified proteins; NP: non-protein components. A division 693 
between cytotoxins (CYT) and neurotoxins (NTX) is given for the three-finger toxins. 694 
 695 
Figure 3: Presence of selected nucleosides and FAD in Naja kaouthia venom shown by 696 
spiking crude venom with 10 μg  of  nucleosides (adenosine, inosine, guanosine) or FAD and 697 
separating the venom components by reverse-phase HPLC. If a the peak of a nucleoside 698 
coincides with the peak of a venom component, and if mass determination yielded the same 699 
mass for the venom component as calculated for the nucleoside, the venom component was 700 
  
32 
judged to consist of the corresponding nucleoside. N. kaouthia venom contains small 701 
amounts of adenosine, guanosine, and traces of inosine, but no FAD. 702 
 703 
Figure 4: (A) Comparison of the phospholipase A2 activity between the venoms of Naja 704 
kaouthia and Micrurus nigrocinctus. N. kaouthia displays some enzymatic activity, 705 
although significantly less than M. nigrocinctus. (B) Comparison of the proteolytic activity 706 
between the venoms of N. kaouthia, M. nigrocinctus, and Bothrops asper, evaluated on 707 
azocasein. N. kaouthia shows negligible proteinase activity. 708 
 709 
Figure 5: Electrospray ionization-mass spectrometry analysis of N. kaouthia venom 710 
fractions 6 and 10 (see Fig.1 and Table 1). Samples were analyzed in enhanced multi-711 
charge positive mode as described in Methods. Fraction 6 (Nk-6) presented a homogeneous 712 
multi-charged series (A) which deconvoluted to an isotope-averaged mass (Mav) of 7826.0 713 
± 0.8 Da (B). The multi-charged series of fraction 10 (Nk-10) (C) showed a main protein 714 
with Mav 7619.0 ± 1.3 Da and a less abundant protein of 7656.0 ± 0.7 Da (D), thus 715 
demonstrating difference between fractions 6 and 10. 716 
 717 
Figure 6: ELISA-based immunoprofiling of human antibodies (Donor 1 IgG: protein A-718 
purified IgG antibodies from Donor 1, Donor 2: protein A-purified IgG antibodies from 719 
Donor 2, Human negative: normal human serum from healthy volunteer, never bitten by a 720 
snake) to the fractions of Naja kaouthia venom separated by RP-HPLC (see Materials and 721 
Methods for details). Toxins with the highest Toxicity Score (4, 5, and 6) are marked with a 722 
skull symbol. 723 
 724 
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Table 1: A
ssignm
ent of the R
P-H
PLC
 isolated fractions of Naja kaouthia venom
 to protein fam
ilies by M
A
LD
I-TO
F-TO
F of selected 
peptide ions from
 in-gel trypsin-digested protein bands. 
 Peak 
%
 
M
ass 
(kD
a)▼
 
Peptide ion 
M
S/M
S-derived or N-terminal (Nt) sequence 
Conf 
(%
) 
Sc 
Protein family;   ~ related protein * 
 
 
 
m/z 
z 
 
 
 
 
1 
0.2 
- 
- 
1 
non-peptidic 
- 
- 
unknow
n 
 
 
 
 
 
 
 
 
 
2 
0.4 
- 
- 
1 
non-peptidic (A
denosine) 
- 
- 
non-peptidic (N
ucleosides) 
 
 
 
 
 
 
 
 
 
3 
0.5 
- 
- 
1 
non-peptidic (G
uanosine) 
- 
- 
non-peptidic (N
ucleosides) 
 
 
 
 
 
 
 
 
 
4 
1.2 
13 
2945.2 
1 
X
EC
H
N
B
B
SSB
TPTTTG
C
SG
G
ETN
C
Y
K
 
99 
25 
3FTx 
three-finger toxin N
aja atra, ~E2IU
03 
 
 
 
 
 
 
 
 
 
5a 
0.3 
67 
1475.7 
1 
SX
D
X
X
B
B
W
EEB
S(R
lo) 
99 
11 
C
ytidyltransferase 
choline-phosphate cytidylyltransferase A
  
isoform
 X
2 Python bivittatus, ~X
P_007440684 
 
 
 
 
 
 
 
 
 
5b 
0.4 
54 
- 
- 
- 
- 
- 
unknow
n 
 
 
 
 
 
 
 
 
 
5c 
3.3 
10 
1728.7 
1014.5 
1316.6 
 
1453.6 
2945.2 
 
1758.8 
1 1 1  1 1  1 
X
EC
H
N
B
B
SSB
A
PTTK
 
B
W
W
SD
H
R
 
V
BPG
V
N
X
N
C
C
R 
 (N
da)G
X
EX
N
C
C
TTD
R
 
X
EC
H
N
B
B
SSB
TPTTTG
C
SG
G
ETN
C
Y
K
 
 X
EC
H
N
B
B
SSB
TPTTK
 
99 
99 
99  
99 
99  
99 
15 
8 
11  
12 
28  
13 
3FTx 
cobrotoxin-c N
aja kaouthia, ~P59276 
  three-finger toxin N
aja atra, ~E2IU
03 
  cobrotoxin-b N
aja kaouthia, ~P59275 
 
 
 
 
 
 
 
 
 
6a 
13.5 
13 
1315.5 
2241.9 
1 1 
TW
C
D
A
FC
SX
R
 
TG
V
D
X
B
C
C
STD
N
C
N
PFPTR
 
99 
99 
13 
16 
3FTx 
alpha-elapitoxin-N
k2a N
aja kaouthia, ~P01391 
 
 
 
 
 
 
 
 
 
6b 
18.8 
10 
1547.7 
2184.9 
1315.5 
2241.9 
1 1 1 1 
R
V
D
X
G
C
A
A
TC
PTV
K
 
TG
V
D
X
B
C
C
STD
N
C
N
PFPTR
 
TW
C
D
A
FC
SX
R
 
TG
V
D
X
B
C
C
STD
N
C
N
PFPTR
 
99 
99 
99 
99 
13 
13 
14 
24 
3FTx 
alpha-elapitoxin-N
k2a N
aja kaouthia, ~P01391 
 
 
 
 
 
 
 
 
 
7 
0.9 
10 
1315.5 
2241.9 
 
2187.9 
1011.5 
1 1  1 1 
TW
C
D
A
FC
SX
R
 
TG
V
D
X
B
C
C
STD
N
C
N
PFPTR
 
 SX
FG
V
TTED
C
PD
G
B
N
X
C
FK
 
W
H
(M
ox)X
V
PG
R
 
99 
99  
99 
82.8 
13 
21  
23 
8 
3FTx 
alpha-elapitoxin-N
k2a N
aja kaouthia, ~P01391 
 m
uscarinic toxin-like prot.2 N
aja kaouthia, 
~P82463 
 
 
 
 
 
 
 
 
 
8 
4.1 
10 
1629.6 
2578.0 
2391.0 
1 1 1 
X
TC
X
N
CPEM
FC
G
K
 
G
C
A
D
TC
PV
G
B
PY
EM
X
EC
C
STD
K
 
X
TC
X
N
CPEM
FC
G
(K
ca)FB
X
C
R
 
99 
99 
99 
16 
28 
11 
3FTx 
w
eak tryptophan-containing neurotoxin, N
aja 
kaouthia, ~P82935 
  
34 
 
 
 
 
 
 
 
 
 
9a 
0.3 
10 
1415.6 
1363.6 
2603.1 
2260.9 
 
962.4 
1 1 1 1  1 
C
B
N
PN
PEPSG
C
R
 
A
X
TM
EG
N
B
A
SW
R
 
ED
H
PV
H
N
X
G
EH
SV
C
D
SV
SA
W
V
TK
 
G
X
D
SSH
W
N
SY
C
TETD
TFX
K
 
 B
Y
FFETK
 
99 
99 
99 
99  
99 
10 
18 
29 
27  
11 
N
erve grow
th factor 
N
G
F N
aja kaouthia, ~P61899 
   N
G
F N
aja sputatrix, ~Q
5Y
F89 
 
 
 
 
 
 
 
 
 
9b 
0.4 
10 
1177.5 
2186.8 
 
2241.9 
1315.5 
 
1629.6 
1 1  1 1  1 
TX
C
Y
N
H
X
TR
 
TSETTEX
C
PD
SW
Y
FC
Y
K
 
 TG
V
D
X
B
C
C
STD
N
C
N
PFPTR
 
TW
C
D
A
FC
SX
R
 
 X
TC
X
N
CPEM
FC
G
K
 
99 
99  
99 
98.8 
 99 
7 
17  
11 
10  
14 
3FTx 
m
uscarinic toxin-like prot.3 N
aja kaouthia, 
~P82464 
 alpha-elapitoxin-N
k2a N
aja kaouthia, ~P01391 
  w
eak neurotoxin N
N
A
M
2 N
aja atra, ~Q
9Y
G
I4 
 
 
 
 
 
 
 
 
 
10 
10.2 
10 
1315.5 
2241.9 
1 1 
TW
C
D
A
FC
SX
R
 
TG
V
D
X
B
C
C
STD
N
C
N
PFPTR
 
99 
99 
13 
15 
3FTx 
alpha-elapitoxin-N
k2a N
aja kaouthia, ~P01391 
 
 
 
 
 
 
 
 
 
11a 
4.9 
15 
1842.7 
1 
SW
W
D
FA
D
Y
G
C
Y
C
G
R
 
99 
10 
Phospholipase A
2  
acidic PLA
2  - 2 N
aja sagittifera, ~P60044 
 
 
 
 
 
 
 
 
 
11b 
2.0 
10 
1826.6 
1669.5 
1232.5 
1697.6 
1842.6 
900.4 
1 1 1 1 1 1 
C
C
B
V
H
D
N
C
Y
N
EA
EK
 
G
D
N
D
A
C
A
A
A
V
C
D
C
D
R
 
N
M
X
B
C
TV
PN
R 
TY
SY
EC
SB
G
TX
TC
K
 
SW
W
D
FA
D
Y
G
C
Y
C
G
R
 
C
W
PY
FK
 
99 
99 
99 
99 
99 
98,2 
22 
20 
13 
16 
18 
9 
Phospholipase A
2  
acidic PLA
2  - 1 N
aja kaouthia, ~P00596 
 
 
 
 
 
 
 
 
 
12a 
2.1 
15 
1842.6 
1 
SW
W
D
FA
D
Y
G
C
Y
C
G
R
 
99 
11 
Phospholipase A
2  
acidic PLA
2  - 1 N
aja sputatrix, ~Q
9I900 
 
 
 
 
 
 
 
 
 
12b 
2.0 
10 
1610.5 
1842.6 
1697.6 
1157.5 
1826.6 
2356.0 
1 1 1 1 1 1 
G
G
N
N
A
C
A
A
A
V
C
D
C
D
R
 
SW
W
D
FA
D
Y
G
C
Y
C
G
R
 
TY
SY
EC
SB
G
TX
TC
K
 
X
SG
C
W
PY
FK
 
C
C
B
V
H
D
N
C
Y
N
EA
EK
 
X
A
A
X
C
FA
G
A
PY
N
N
N
N
Y
N
X
D
X
K
 
99 
99 
99 
99 
99 
99 
20 
19 
14 
13 
20 
22 
Phospholipase A
2  
acidic PLA
2  - 1 N
aja atra, ~P00598 
 
 
 
 
 
 
 
 
 
13a 
2.5 
22 
1842.6 
1 
SW
W
D
FA
D
Y
G
C
Y
C
G
R
 
99 
9 
Phospholipase A
2  
acidic PLA
2  - D
 N
aja sputatrix, ~Q
9I900 
 
 
 
 
 
 
 
 
 
13b 
5 
10 
2829.3 
1087.4 
1798.8 
 
1842.6 
1 1 1  1 
TC
PA
G
B
N
X
C
Y
B
M
FM
V
SN
B
TV
PV
B
R
 
Y
V
C
C
N
TD
R
 
N
SX
X
V
(K
ca)Y
V
C
C
N
TD
R
 
 SW
W
D
FA
D
Y
G
C
Y
C
G
R
 
99 
99 
99  
99 
14 
10 
15  
14 
3FTx 
cytotoxin 3 N
aja kaouthia, ~P01446 
  Phospholipase A
2  
  
35 
acidic PLA
2  - D
 N
aja sputatrix, ~Q
9I900 
 
 
 
 
 
 
 
 
 
14a 
1.3 
25 
1087.4 
1 
Y
V
C
C
N
TD
R
 
 
91.6 
7 
3FTx 
cytotoxin V
C
-1 Naja oxiana, ~Q
9PS33 
 
 
 
 
 
 
 
 
 
14b 
1.1 
10 
2829.3 
1087.4 
1798.8 
1 1 1 
TC
PA
G
B
N
X
C
Y
B
M
FM
V
SN
B
TV
PV
B
R
 
Y
V
C
C
N
TD
R
 
N
SX
X
V
(K
ca)Y
V
C
C
N
TD
R
 
99 
99 
99 
10 
12 
15 
3FTx 
cytotoxin 2 N
aja kaouthia, ~P01445 
 
 
 
 
 
 
 
 
 
15 
2.4 
11 
1412.6 
1798.8 
1568.7 
1087.4 
 
1420.6 
1 1 1 1  1 
M
FM
M
SD
X
TX
PV
K
 
N
SX
X
V
(K
ca)Y
V
C
C
N
TD
R
 
M
FM
M
SD
X
TX
PV
B
R
 
Y
V
C
C
N
TD
R
 
 C
H
N
TB
X
PFX
Y
K
 
99 
99 
99 
99  
99 
11 
15 
14 
10  
16 
3FTx 
cytotoxin V
C
-1 Naja oxiana, ~Q
9PS33 
   cytotoxin 5V
 N
aja atra, ~Q
9W
716 
 
 
 
 
 
 
 
 
 
16a  
5.0 
21 
1087.5 
1 
Y
V
C
C
N
TD
R
 
m
an 
m
an 
3FTx 
three-finger toxin N
aja atra, ~E2IU
04 
 
 
 
 
 
 
 
 
 
16b 
3.7 
10 
2861.3 
1412.6 
1568.7 
1798.7 
1087.4 
1 1 1 1 1 
TC
PA
G
B
N
X
C
Y
B
M
FM
M
SD
X
TX
PV
B
R
 
M
FM
M
SD
X
TX
PV
K
 
M
FM
M
SD
X
TX
PV
B
R
 
N
SX
X
V
(K
ca)Y
V
C
C
N
TD
R
 
Y
V
C
C
N
TD
R
 
99 
99 
99 
99 
99 
11 
11 
17 
11 
10 
3FTx 
three-finger toxin N
aja atra, ~E2IU
04 
 
 
 
 
 
 
 
 
 
17a 
0.5 
12 
2141.9 
2270.0 
930.4 
913.4 
1810.8 
1495.6 
1 1 1 1 1 1 
A
D
V
TFD
SN
TA
FESX
V
V
SPD
K
 
A
D
V
TFD
SN
TA
FESX
V
V
SPD
BK
 
EW
A
V
G
X
A
G
K
 
SPPG
N
W
B
K
 
TV
EN
V
G
V
SBV
A
PD
N
PER
 
FD
G
SPC
V
X
G
SPG
FR
 
99 
99 
99 
99 
99 
99 
15 
17 
13 
10 
19 
19 
O
hanin/vespryn 
thaicobrin Naja kaouthia, ~P82885 
 
 
 
 
 
 
 
 
 
17b 
1.2 
10 
1771.8 
2918.2 
1087.4 
 
1798.8 
1 1 1  1 
SSX
X
V
(K
ca)Y
V
C
C
N
TD
R
 
G
C
X
D
V
CPB
SSX
X
V
B
Y
V
C
C
N
TD
R
C
N
 
Y
V
C
C
N
TD
R
 
 N
SX
X
V
(K
ca)Y
V
C
C
N
TD
R
 
99 
83,4 
99  
99 
14 
7 
11  
16 
3FTx 
cytotoxin 4N
 N
aja atra, ~Q
9W
6W
9 
  cytotoxin 3a Naja atra, ~Q
98959 
 
 
 
 
 
 
 
 
 
18a 
0.8 
13 
1315.5 
1 
TW
C
D
A
FC
SX
R
 
94.7 
8 
3FTx 
alpha-elapitoxin-N
k2a N
aja kaouthia, ~P01391 
 
 
 
 
 
 
 
 
 
18b 
4.6 
10 
1087.4 
948.4 
924.4 
2918.3 
1771.8 
1 1 1 1 1 
Y
V
C
C
N
TD
R
 
G
C
X
D
V
CPK
 
M
FM
V
A
TPK
 
G
C
X
D
V
CPB
SSX
X
V
B
Y
V
C
C
N
TD
R
C
N
 
SSX
X
V
(K
ca)Y
V
C
C
N
TD
R
 
99 
99 
99 
99 
99 
10 
10 
10 
11 
14 
3FTx 
cytotoxin 8 N
aja atra, ~Q
91124 
 
 
 
 
 
 
 
 
 
19 
0.2 
10 
- 
- 
- 
- 
- 
unknow
n 
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20a 
0.1 
57 
- 
- 
- 
- 
- 
unknow
n 
 
 
 
 
 
 
 
 
 
20b 
0.5 
20 
2102.9 
1409.7 
1 1 
X
G
C
G
EN
X
FM
SSBPY
A
W
SR
 
V
X
B
SW
Y
D
EN
B
K
 
99 
99 
16 
11 
C
ysteine-rich secretory protein 
natrin-2 N
aja atra, ~Q
7ZZN
8 
 
 
 
 
 
 
 
 
 
20c 
0.1 
12 
1810.9 
2270.0 
1495.7 
1 1 1 
TV
EN
V
G
V
SBV
A
PD
N
PER
 
A
D
V
TFD
SN
TA
FESX
V
V
SPD
BK
 
FD
G
SPC
V
X
G
SPG
FR
 
99 
99 
99 
17 
10 
12 
O
hanin/vespryn 
thaicobrin Naja kaouthia, ~P82885 
 
 
 
 
 
 
 
 
 
20d 
0.1 
10 
- 
- 
- 
- 
- 
unknow
n 
 
 
 
 
 
 
 
 
 
21 
0.3 
11 
1296.6 
1168.5 
1 1 
B
Y
X
W
EW
TD
R
 
Y
X
W
EW
TD
R
 
99 
99 
11 
12 
C
-type lectin/lectin-like 
LP-Pse-6 C
TL Pseudonaja m
odesta, ~R
4G
314 
 
 
 
 
 
 
 
 
 
22a 
1.1 
21 
2013.9 
1434.7 
1553.6 
3174.5 
1870.8 
1258.4 
1784.8 
1 1 1 1 1 1 1 
V
X
EG
X
B
C
G
ESX
Y
M
SSN
A
R
 
ZB
EX
V
D
X
H
N
SX
R
 
M
EW
Y
PEA
A
SN
A
ER
 
N
FV
Y
G
V
G
A
N
PPG
SV
TG
H
Y
TB
X
V
W
Y
B
TY
R
 
TW
TEX
X
H
X
W
H
D
EY
K
 
SN
C
PA
SC
FC
R 
W
A
N
TC
SX
N
H
SPD
N
X
R
 
99 
99 
99 
99 
99 
99 
99 
23 
17 
16 
15 
21 
14 
23 
C
ysteine-rich secretory protein 
natrin-1 N
aja atra, ~Q
7T1K
6 
 
 
 
 
 
 
 
 
 
22b 
0.1 
15 
1553.6 
1784.7 
1870.8 
2013.9 
1 1 1 1 
M
EW
Y
PEA
A
SN
A
ER
 
W
A
N
TC
SX
N
H
SPD
N
X
R
 
TW
TEX
X
H
X
W
H
D
EY
K
 
V
X
EG
X
B
C
G
ESX
Y
M
SSN
A
R
 
99 
99 
99 
99 
13 
18 
15 
14 
C
ysteine-rich secretory protein 
natrin-1 N
aja atra, ~Q
7T1K
6 
 
 
 
 
 
 
 
 
 
22c 
0.1 
12 
1168.5 
1296.6 
1 1 
Y
X
W
EW
TD
R
 
B
Y
X
W
EW
TD
R
 
99 
97.6 
11 
8 
C
-type lectin/lectin-like 
LP-Pse-6 C
TL Pseudonaja m
odesta, ~R
4G
314 
 
 
 
 
 
 
 
 
 
22d 
0.1 
10 
1168.5 
1 
Y
X
W
EW
TD
R
 
98.5 
7 
C
-type lectin/lectin-like 
LP-Pse-6 C
TL Pseudonaja m
odesta, ~R
4G
314 
 
 
 
 
 
 
 
 
 
23a 
0.1 
56 
1470.8 
1695.9 
1635.8 
2024.0 
1 1 1 1 
X
PV
Y
SA
Y
V
Y
N
PG
K
 
SSTFTX
TN
X
V
PB
FX
K
 
G
H
X
N
PN
G
H
B
PD
Y
SA
K
 
EV
V
D
SFB
D
H
CPB
FFX
R
 
99 
99 
99 
99 
12 
8 
13 
9 
N
ucleotidase 
endonuclease dom
ain-containing 1 prot M
icrurus 
fulvius, ~tr|U
3FC
T9 
 
 
 
 
 
 
 
 
 
 
23b 
0.2 
26 
2080.9 
2023.8 
1695.8 
1 1 1 
G
EV
V
D
SFB
D
H
CPB
FFX
R
 
EV
V
D
SFB
D
H
CPB
FFX
R
 
SSTFTX
TN
X
V
PB
FX
K
 
99 
99 
96.9 
10 
14 
8 
N
ucleotidase 
endonuclease dom
ain-containing 1 prot, M
icrurus 
fulvius, ~U
3FC
T9 
 
 
 
 
 
 
 
 
 
24a 
0.1 
250 
1430.8 
1 
Y
X
EFY
V
X
V
D
N
R
 
99 
10 
M
etalloproteinase 
kaouthiagin Naja kaouthia, P82942 
 
 
 
 
 
 
 
 
 
24b 
0.2 
66 
2689.1 
1099.6 
1471.7 
1 1 1 
H
D
C
D
X
PEX
C
TG
B
SA
EC
PTD
SX
B
R
 
D
Y
B
EY
X
X
R 
TA
PA
FB
FSSC
SX
R
 
99 
99 
99 
7 9 
17 
M
etalloproteinase 
kaouthiagin Naja kaouthia, P82942 
  
37 
1430.8 
1 
Y
X
EFY
V
X
V
D
N
R
 
99 
15 
 
 
 
 
 
 
 
 
 
24c 
0.2 
57 
1099.5 
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1471.7 
1430.7 
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X
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D
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D
X
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Y
X
EFY
V
X
V
D
N
R
 
99 
99 
99 
99 
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13 
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M
etalloproteinase 
kaouthiagin Naja kaouthia, P82942 
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M
etalloproteinase 
kaouthiagin Naja kaouthia, ~P82942 
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FY
TFD
SEA
X
V
K
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V
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99 
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25b 
0.3 
108 
1434.7 
1244.7 
2106.1 
1634.7 
1518.9 
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V
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V
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B
3 
 
 
 
 
 
 
 
 
 
25c 
0.1 
61 
1449.8 
2421.3 
1719.0 
1459.8 
1 1 1 1 
V
V
SX
N
V
X
C
TEC
R
 
FH
EC
N
X
G
N
X
X
C
D
A
V
V
Y
N
N
X
R
 
ETPV
X
SN
PG
PY
X
EFR
 
Y
X
G
Y
X
N
V
X
FD
D
K
 
99 
99 
99 
93,5 
8 9 
10 
7 
5'-nucleotidase 
ecto-5'-nucleotidase 1 M
icrurus fulvius, ~U
3FY
P9 
 
 
 
 
 
 
 
 
 
26a 
0.1 
250 
1339.7 
1718.9 
 
2517.2 
1 1  1 
EG
W
Y
V
N
M
G
PM
R
 
TFV
TA
D
Y
V
X
V
CSTSR
 
 SPX
EEC
FB
B
N
D
Y
EEFX
EX
A
R
 
99 
99  
99 
9 
15  
20 
L
-am
ino acid oxidase 
L-am
ino-acid oxidase N
aja atra, ~A
8Q
L58 
 L-am
ino-acid oxidase N
aja oxiana, ~P0D
I91 
 
 
 
 
 
 
 
 
 
26b 
0.1 
70 
2030.0 
1386.7 
1875.1 
1 1 1 
FFY
X
D
G
N
EN
FH
V
SX
TA
R
 
B
X
D
X
FV
H
D
FPR 
X
X
X
N
X
PX
N
A
B
SX
PX
TV
R
 
99 
99 
99 
12 
10 
13 
C
obra venom
 factor 
C
V
F Naja kaouthia, Q
91132 
 
 
 
 
 
 
 
 
 
 
26c 
0.3 
55 
2673.3 
2922.5 
2517.2 
1 1 1 
R
SPX
EEC
FB
B
N
D
Y
EEFX
EX
A
R
 
FG
X
B
X
N
EFFB
EN
EN
A
W
Y
Y
X
N
N
X
R
 
SPX
EEC
FB
B
N
D
Y
EEFX
EX
A
R
 
99 
99 
99 
8 
10 
17 
L
-am
ino acid oxidase 
L-am
ino-acid oxidase N
aja oxiana, ~P0D
I91 
 
 
 
 
 
 
 
 
 
27 
0.3 
46 
1603.8 
1235.7 
1 1 
V
Y
EM
V
N
A
X
N
TM
Y
R
 
V
TX
D
X
FG
EW
R
 
99 
99 
11 
12 
M
etalloproteinase 
m
ocarhagin, N
aja m
ossam
bica, ~Q
10749 
 
 
 
 
 
 
 
 
 
28 
0.9 
44 
2713.2 
1 
D
D
C
D
X
PEX
C
TG
B
SA
EC
PTD
V
FB
R
 
99 
11 
M
etalloproteinase 
  
38 
1207.6 
1807.9 
2983.4 
1 1 1 
A
TX
D
X
FG
EW
R
 
Y
X
EFY
(M
dt)V
V
D
N
X
M
Y
R 
A
A
B
D
D
C
D
X
PEX
C
TG
B
SA
EC
PTD
V
FB
R
 
99 
99 
99 
10 
12 
10 
cobrin N
aja kaouthia, ~Q
9PV
K
7 
 
 
 
 
 
 
 
 
 
 * C
ysteine residues are carbam
idom
ethylated, unless underlined. C
onfidence (Conf) and Score (Sc) values are calculated by the Paragon algorithm
 
of ProteinPilot ® (A
B
Sciex) ▼
:  estim
ated m
ass by SD
S-PA
G
E under reducing conditions, in kD
a. 
: observed isotope-averaged m
asses as 
determ
ined by nESI-M
S of selected R
P-H
PLC
 peaks, in D
a. X
: Leu/Ile; B
: Lys/G
ln; Z: pyroglutam
ate (2-oxo-pyrrolidone carboxylic acid). 
Possible, although unconfirm
ed/am
biguous am
ino acid m
odifications suggested by the autom
ated identification softw
are are show
n in parentheses, 
w
ith the follow
ing abbreviations: ox: oxidized; da: deam
idated; ca: carbam
yl; am
: am
ide; na: N
a cation; al: am
m
onia loss; dl: delta
H
2C
2; m
an: m
anually 
interpreted M
S/M
S spectrum
. 
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Table 2: M
edian lethal doses (LD
50 s) of Naja kaouthiua venom
 and the R
P-H
PLC
 isolated fractions 
Peak 
%
 
Protein family 
LD
50 
(95%
 C.L.) 
Reported LD
50  
(mg/kg) 
Toxicity Score 1 
%
 / LD
50 
(kg/mg) 
W
hole venom
 
 
 
0.24 
(0.12-0.41) 
0.115* 
423.2 
4 
1.2 
3FTx 
three-finger toxin Naja atra, ~E2IU
03 
0.24 
(0.12-0.41) 
 
15.4 
5 
4.0 
(3:4:33 
m
ix
2) 
C
ytidyltransferase (7.5%
) 
choline-phosphate cytidylyltransferase A
  
isoform
 X
2 Python bivittatus, ~X
P_007440684 
U
nknow
n (10%
) 
3FTx (82.5%
) 
cobrotoxin-c Naja kaouthia, ~P59276 
three-finger toxin Naja atra, ~E2IU
03 
cobrotoxin-b Naja kaouthia, ~P59275 
0.07 
(0.001-0.19) 
80 (cobrotoxin-
c), 400 
(cobrotoxin-b) 
[M
eng et al., 
2002] 
41.3 
6 
32.3 
3FTx 
alpha-elapitoxin-N
k2a Naja kaouthia, ~P01391 
0.10 
(0.02-0.18) 
0.1 [K
arlsson, 
1973] 
326 
7 
0.9 
3FTx 
alpha-elapitoxin-N
k2a Naja kaouthia, ~P01391 
m
uscarinic toxin-like prot.2 Naja kaouthia, ~P82463 
0.36 
(0.17-0.72) 
 
2.5 
8 
8.0 
3FTx 
w
eak tryptophan-containing neurotoxin, Naja kaouthia, ~P82935 
~2 
 
~4 
9 
0.7 
(3:4 m
ix
2) 
N
erve grow
th factor (43%
) 
N
G
F Naja kaouthia, ~P61899 
N
G
F Naja sputatrix, ~Q
5Y
F89 
3FTx (57%
) 
m
uscarinic toxin-like prot.3 Naja kaouthia, ~P82464 
alpha-elapitoxin-N
k2a Naja kaouthia, ~P01391 
w
eak neurotoxin N
N
A
M
2 Naja atra, ~Q
9Y
G
I4 
>1 
 
<1 
  
40 
10 
10.2 
3FTx 
alpha-elapitoxin-N
k2a Naja kaouthia, ~P01391 
>10 
 
<1 
11 
6.9 
(49:20 
m
ix
2) 
Phospholipase A
2  
acidic PLA
2  - 2 Naja sagittifera, ~P60044 (71%
) 
acidic PLA
2  - 1 Naja kaouthia, ~P00596 (29%
) 
5.38 
(2.01-55.94) 
10 [C
hum
an et 
al., 2000] 
1.3 
12 
4.1 
(51:49 
m
ix
2) 
Phospholipase A
2  
acidic PLA
2  - 1 Naja sputatrix, ~Q
9I900 (51%
) 
acidic PLA
2  - 1 Naja atra, ~P00598 (49%
) 
3.74 
(2.17-8.75) 
 
1.1 
13 
7.5 
(1:2 m
ix
2) 
Phospholipase A
2  (33%
) 
acidic PLA
2  - D
 Naja sputatrix, ~Q
9I900 
3FTx (66%
) 
cytotoxin 3 Naja kaouthia, ~P01446 
0.9 
(0.09-1.29) 
 
8.3 
14 
2.4 
(27:23 
m
ix
2) 
3FTx 
cytotoxin V
C
-1 Naja oxiana, ~Q
9PS33 (54%
) 
cytotoxin 2 Naja kaouthia, ~P01445 (46%
) 
1.60 
(1.21-2.28) 
1.2 (cytotoxin 2) 
[Joubert and 
Taljaard, 1980b] 
1.57 
15 
2.4 
3FTx 
cytotoxin V
C
-1 Naja oxiana, ~Q
9PS33 
1-2.5 
 
<2.5 
16 
8.7 
3FTx 
three-finger toxin Naja atra, ~E2IU
04 
0.75 
(0.30-1.66) 
 
11.6 
17 
1.7 
(5:12 m
ix
2) 
O
hanin/vespryn (29%
) 
thaicobrin Naja kaouthia, ~P82885 
3FTx (71%
) 
cytotoxin 4N
 Naja atra, ~Q
9W
6W
9 
cytotoxin 3a Naja atra, ~Q
98959 
1.36 
(0.62-2.03) 
 
1.25 
18 
5.4 
(4:23 m
ix
2) 
3FTx (15%
) 
alpha-elapitoxin-N
k2a Naja kaouthia, ~P01391 
3FTx (85%
) 
cytotoxin 8 Naja atra, ~Q
91124 
1.00 
(0.43-2.93) 
 
5.4 
19 
0.2 
U
nknow
n 
>0.25 
 
<1 
  
41 
20 
0.8 
(2:5:1 
m
ix
2) 
U
nknow
n (25%
) 
C
ysteine-rich secretory protein (62.5%
) 
natrin-2 Naja atra, ~Q
7ZZN
8 
O
hanin/vespryn (12.5%
) 
thaicobrin Naja kaouthia, ~P82885 
>1 
 
<1 
21 
0.3 
C
-type lectin/lectin-like 
LP-Pse-6 C
TL Pseudonaja m
odesta, ~R
4G
314 
>0.5 
 
<1 
22 
1.4 
(6:1 m
ix
2) 
C
ysteine-rich secretory protein (86%
) 
natrin-1 Naja atra, ~Q
7T1K
6 
C
-type lectin/lectin-like (14%
) 
LP-Pse-6 C
TL Pseudonaja m
odesta, ~R
4G
314 
>1.5 
 
<1 
23 
0.3 
N
ucleotidase 
endonuclease dom
ain-containing 1 prot M
icrurus fulvius, ~tr|U
3FC
T9 
 
 
N
.t. 
24 
1.2 
M
etalloproteinase 
kaouthiagin Naja kaouthia, P82942 
 
 
N
.t. 
25 
0.5 
(4:1 m
ix
2) 
Phosphodiesterase (80%
) 
phosphodiesterase 1 M
icrurus fulvius, ~U
3FA
B
3 
5'-nucleotidase (20%
) 
ecto-5'-nucleotidase 1 M
icrurus fulvius, ~U
3FY
P9 
>0.25 
 
<2 
26 
0.5 
(1:1:3 
m
ix
2) 
L-am
ino acid oxidase (20%
) 
L-am
ino-acid oxidase Naja atra, ~A
8Q
L58 
L-am
ino-acid oxidase Naja oxiana, ~P0D
I91 
C
obra venom
 factor (20%
) 
C
V
F Naja kaouthia, Q
91132 
L-am
ino acid oxidase (60%
) 
L-am
ino-acid oxidase Naja oxiana, ~P0D
I91 
 
 
N
.t. 
27 
0.3 
M
etalloproteinase 
m
ocarhagin, Naja m
ossam
bica, ~Q
10749 
 
 
N
.t. 
28 
0.9 
M
etalloproteinase 
cobrin Naja kaouthia, ~Q
9PV
K
7 
 
 
N
.t. 
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*http://snakedatabase.org/pages/LD
50.php#legendA
ndD
efinitions  
1 Toxicity Score w
as defined as the ratio of protein fraction abundance (%
) in the venom
 divided by its estim
ated m
edian lethal dose 
(LD
50 ) for C
D
-1 m
ice by i.v. injection. 
2 M
ix indicates that the fraction did not contain a pure, isolated toxin, but instead a m
ixture of 2-4 different toxins in variable ratios 
indicated in the table. 
N
.t. : not tested 
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